Lecanemab dosing for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study compares different doses of the drug lecanemab to see how well they work in people with early Alzheimer's disease or mild cognitive impairment caused by Alzheimer's. It aims to find the best dose for slowing memory decline in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild cognitive impairment or early Alzheimer's disease, confirmed by a brain scan (PIB-PET).
- You are between 50 and 85 years old.
- You are not currently participating in any other research studies.
- You can communicate with the study team and follow the study procedures.
- You do not have other brain disorders, serious medical conditions, infections, or psychiatric conditions that could affect your memory.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This trial tests whether a monoclonal antibody drug can help people with early Alzheimer's disease or mild cognitive impairment. The drug targets amyloid plaques in the brain, which are detected using a special PET scan before treatment.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
Hear when a new MCI-AD, Early Stage Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.